Journal of Cancer Science and Research
Open Access

Abstract

Rational Combinations of Active and Passive Immunotherapy Mobilize Immune and Clinical Responses in Terminal Cancers

Chikuda Junichiro*

Solid tumors encroach on the hosts immune microenvironment to favor its own proliferation. Strategies to enhance the specificity of the endogenous T cell population against tumors have been met with limited clinical success. We aimed to devise a 2-tier protocol coupling in vivo whole antigen priming with ex vivo cellular expansion to clinically evaluate survival in patients following re-infusion of primed, autologous T cells, determining treatment efficacy. Treatment commenced with the acquisition of whole tumor antigens from tumor cell lines corresponding with patients primary malignancy. Lysate mixture was inoculated intradermally while Peripheral Blood Mononuclear Cells (PBMCs) were periodically extracted via phlebotomy and expanded in culture ex vivo for re-infusion. Post treatment tumor- specific T cell response and cytotoxicity was confirmed via ELI Spot and Real-Time Cell Analyzing (RTCA) Assay. Because "cancer" refers to a class of diseases, it is unlikely that there will ever be a single "cure for cancer" any more than there will be a single treatment for all infectious diseases. Angiogenesis inhibitors were once thought to have potential as a "silver bullet" treatment applicable to many types of cancer, but this has not been the case in practice.

Published Date: 2021-11-25; Received Date: 2021-11-03